| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| RVL Pharmaceuticals plc | EVP, Research & Development | Ordinary Shares | 136,141 | $4,248 | $0.0312 | 18 May 2022 | Direct |
| Osmotica Pharmaceuticals plc | EVP, Research & Development | Share Option (Right to Buy) | 216,944 | 04 Nov 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000110465922063394-devries-tina-marie-2022-05-18 | RVL Pharmaceuticals plc | 18 May 2022 | 1 | -$7,626 | 4 | EVP, Research & Development | 20 May 2022, 16:28 |
| /report/000110465922007841-devries-tina-marie-2022-01-24 | RVL Pharmaceuticals plc | 24 Jan 2022 | 1 | -$10,856 | 4 | EVP, Research & Development | 26 Jan 2022, 15:31 |
| /report/000110465921135643-devries-tina-marie-2021-11-04 | Osmotica Pharmaceuticals plc | 04 Nov 2021 | 1 | $0 | 4 | EVP, Research & Development | 08 Nov 2021, 15:09 |
| /report/000110465921069876-devries-tina-marie-2021-05-18 | Osmotica Pharmaceuticals plc | 18 May 2021 | 1 | -$20,177 | 4 | EVP, Research & Development | 20 May 2021, 16:05 |